🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Iparomlimab and Tuvonralimab

Neoadjuvant Iparomlimab and Tuvonralimab Plus Chemotherapy-eclipse for Locally Advanced Cervical Cancer (NICE-CC) NCT07055399Phase 21 site📍 Fuzhou Fujian Cancer Hospital · Tests: neoadjuvant chemo-immunotherapy: Iparomlimab and tuvonralimab plus cisplatin,nab-paclitaxel for 1 cycle and Iparomlimab… A Multicenter Randomized Controlled Phase II Trial of Iparomlimab and Tuvonralimab (QL1706) Combined With SOX Chemotherapy Versus Chemotherapy Alone in the Treatment of Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma NCT06829797Phase 21 site📍 Jinan Shandong Provincial Hospital · Tests: Neoadjuvant Therapy(QL1706+SOX Chemotherapy), Neoadjuvant Therapy(SOX Chemotherapy), Radical surgery (D2), Drug: Adjuva… Iparomlimab and Tuvonralimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy for CC NCT06878222Phase 21 site📍 Shanghai Obstetrics & Gynecology Hospital of Fudan University · Tests: Neoadjuvant Chemotherapy, Neoadjuvant Chemotherapy, Immunotherapy, Radical surgery, Fertility-preserving surgery PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC NCT07416058Phase 22 sites📍 Guangzhou📍 Guangzhou Guangdong Association of Clinical Trials · Tests: QL1706 (bispecific antibody targeting PD-1 and CLTA-4) Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy NCT07372079Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: QL1706 combined with Chemotherapy Iparomlimab and Tuvonralimab (QL1706) for Intermediate Trophoblastic Tumors NCT06941766Phase 1, Phase 21 site📍 Beijing Peking Union Medical College Hospital · Tests: QL1706, Chemotherapy Iparomlimab and Tuvonralimab Plus Paclitaxel and Platinum as Neoadjuvant Therapy for Locally Advanced Cervical Cancer NCT07646301Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Iparomlimab and Tuvonralimab (QL1706), Paclitaxel, Cisplatin, Carboplatin Cryoablation Combined With Hepatic Arterial Infusion of Iparomlimab and Tuvonralimab (QL1706), Intravenous Dacarbazine, and Oral Lenvatinib in Patients With Liver Metastases From Malignant Melanoma: a Single-arm, Phase II, Prospective Trial NCT07847359Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Cryoablation, Iparomlimab and Tuvonralimab, Dacarbazine, Lenvatinib Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer. NCT07343791EARLY Phase 11 site📍 Nanjing JIANG LONGWEI · Tests: DC-CIK combined with regorafenib ,Iparomlimab and Tuvonralimab Injection Iparomlimab/Tuvonralimab Combined With Nab-paclitaxel and Cisplatin as Neoadjuvant Therapy for Locally Advanced Cervical Cancer NCT07876154Phase 21 site📍 Xi'an Xijing Hospital · Tests: Iparomlimab/Tuvonralimab, nab-paclitaxel, Cisplatin, Carboplatin (AUC 5) BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or Oligometastases NCT07062055Phase 21 site📍 Jinan Shandong Cancer Hospital and Institute · Tests: Anti-VEGF, Immunotherapy, Local Therapy, hepatic arterial infusion chemotherapy (HAIC), Surgical Resection SFRT+Sequential Hypofractionated/Conventional Fractionated RT+Iparomlimab and Tuvonralimab for Relapsed/Refractory Solid Tumors NCT06936748Phase 21 site📍 Nanchang Second Affiliated Hospital of Nanchang University · Tests: Spatially Fractionated Radiation Therapy Followed by Sequential Hypofractionated or Conventional Fractionated Radiother… Iparomlimab and Tuvonralimab in HNSCC NCT07090317Phase 21 site📍 Shanghai Shanghai Ninth People's Hospital Affiliated to Shanghai Jia… · Tests: Iparomlimab and Tuvonralimab Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma NCT06932068Phase 229 sites📍 Zhengzhou📍 Binzhou📍 Dezhou Qilu Hospital of Shandong University · Tests: Iparomlimab and Tuvonralimab (QL1706), Oxallplation, Capectitabine Tablets QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer NCT06951997Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: QL1706, Chidamide, Gemcitabine, Nab-paclitaxel Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer NCT07180160Phase 21 site📍 Shanghai Wenjin Yin · Tests: QL1706, CDK4/6 inhibitor, Fulvestrant Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer NCT07392346Phase 21 site📍 Beijing Dai, Guanghai · Tests: Fruquintinib, Iparomlimab and Tuvonralimab, Paclitaxel (albumin-bound) Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer NCT07396324Phase 21 site📍 Shanghai RenJi Hospital · Tests: Iparomlimab and Tuvonralimab, Paclitaxel, Carboplatin Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC NCT07801287Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: Iparomlimab/Tuvonralimab plus SBRT and Lenvatinib SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Cancer NCT06864013Phase 21 site📍 Hangzhou First Affiliated Hospital of Zhejiang University · Tests: Experimental, Control Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer NCT06942416Phase 21 site📍 Jinan Shandong Cancer Hospital and Institute · Tests: Paclitaxel and Cisplatin/ Carboplatin, Iparomlimab and Tuvonralimab, Radiotherapy QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma. NCT06749899Phase 319 sites📍 Fuzhou📍 Dongguan📍 Foshan Sun Yat-Sen University Cancer Center · Tests: QL1706, Gemcitabine, Cisplatin, Intensity-modulated radiotherapy Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC NCT07389629Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: QL1706 Combined With Lenvatinib Radiotherapy Plus CAPOX, and Iparomlimab and Tuvonralimab (QL1706) as Neoadjuvant Therapy for LARC NCT07291401Phase 21 site📍 Wuhan Zhongnan Hospital · Tests: lparomlimab and Tuvonralimab Injection and CPAOX and radiotherapy Neoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction Cancer NCT07867392Phase 21 site📍 Shanghai Ruijin Hospital · Tests: Iparomlimab and Tuvonralimab (QL1706), nab-P-SOX（nab-paclitaxel, oxaliplatin, S-1） Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC NCT07447570Phase 21 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: Iparomlimab and Tuvonralimab injection, Hypofractionated Radiotherapy, Chemotherapy Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC NCT07232654Phase 21 site📍 Beijing Cancer Institute and Hospital, Chinese Academy of Medical S… · Tests: Iparomlimab/Tuvonralimab, Cisplatin, Brachytherapy and External Beam Radiotherapy Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer NCT07267078Phase 21 site📍 Beijing Peking Union Medical College Hospital · Tests: Tuvonralimab/Iparomlimab combination with GEMOX chemotherapy Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in pMMR/MSS Locally Advanced Rectal Cancer NCT07686640Phase 31 site📍 Jinan Shandong Cancer Hospital and Institute · Tests: Short-Course Radiotherapy, Consolidation treatment (With ICIs), Consolidation treatment (Without ICIs) Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma NCT07014150Phase 21 site📍 Beijing Peking Union Medical College Hospital · Tests: Lenvatinib, Iparomlimab and Tuvonralimab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy